BACKGROUND: Urinary bladder transitional-cell carcinoma is still challenging because the mechanisms underlying the tumor progression are still largely unknown. Transforming growth factor beta1 (TGF-beta1) is considered a crucial molecule in the tumorigenesis of urinary bladder carcinoma. Many studies have indicated that it is also associated with epithelial-mesenchymal transition, angiogenesis, migration and metastases in many types of malignant tumors. MATERIALS AND METHODS: We blocked the TGF-beta signal pathway in T24 human bladder cancer cells with a siRNA (TsiRNA), which targets the TGF-beta type I receptor and evaluated the effects of TGF-beta1 and TsiRNA on the cell motility and invasiveness by Matrigel migration assay, wound-healing assay and Matrigel invasion assay. RT-PCR and Western blotting analysis were used to examine the effects of TGF-beta1 and TsiRNA on the expression of TGFBRI and genes, which are related to tumor migration and invasion. RESULTS: While exogenous TGF-beta1 enhanced the migration and invasion of T24 cells, TsiRNA significantly suppressed them. RT-PCR and Western blotting analysis revealed that TsiRNA could downregulate both the expression of alpha3, beta1 and alpha2 integrin subunits and the activity of matrix metalloproteinase 9 enhanced by exogenous TGF-beta1. CONCLUSION: Our study suggested that inhibition of TGF-beta1 signaling pathway by siRNA could be beneficial in the treatment of patients with metastatic bladder cancer.
BACKGROUND: Urinary bladder transitional-cell carcinoma is still challenging because the mechanisms underlying the tumor progression are still largely unknown. Transforming growth factor beta1 (TGF-beta1) is considered a crucial molecule in the tumorigenesis of urinary bladder carcinoma. Many studies have indicated that it is also associated with epithelial-mesenchymal transition, angiogenesis, migration and metastases in many types of malignant tumors. MATERIALS AND METHODS: We blocked the TGF-beta signal pathway in T24 humanbladder cancer cells with a siRNA (TsiRNA), which targets the TGF-beta type I receptor and evaluated the effects of TGF-beta1 and TsiRNA on the cell motility and invasiveness by Matrigel migration assay, wound-healing assay and Matrigel invasion assay. RT-PCR and Western blotting analysis were used to examine the effects of TGF-beta1 and TsiRNA on the expression of TGFBRI and genes, which are related to tumor migration and invasion. RESULTS: While exogenous TGF-beta1 enhanced the migration and invasion of T24 cells, TsiRNA significantly suppressed them. RT-PCR and Western blotting analysis revealed that TsiRNA could downregulate both the expression of alpha3, beta1 and alpha2 integrin subunits and the activity of matrix metalloproteinase 9 enhanced by exogenous TGF-beta1. CONCLUSION: Our study suggested that inhibition of TGF-beta1 signaling pathway by siRNA could be beneficial in the treatment of patients with metastatic bladder cancer.
Authors: Patrick Michl; Antoine R Ramjaun; Olivier E Pardo; Patricia H Warne; Martin Wagner; Richard Poulsom; Corrado D'Arrigo; Kenneth Ryder; Andre Menke; Thomas Gress; Julian Downward Journal: Cancer Cell Date: 2005-06 Impact factor: 31.743
Authors: Y Maehara; Y Kakeji; A Kabashima; Y Emi; A Watanabe; K Akazawa; H Baba; S Kohnoe; K Sugimachi Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Manuel A Friese; Jörg Wischhusen; Wolfgang Wick; Markus Weiler; Günter Eisele; Alexander Steinle; Michael Weller Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: Gayathri Subramanian; Roderich E Schwarz; Linda Higgins; Glenn McEnroe; Sarvajit Chakravarty; Sundeep Dugar; Michael Reiss Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: Sounak Gupta; Andrew M Hau; Hikmat A Al-Ahmadie; Jyoti Harwalkar; Aaron C Shoskes; Paul Elson; Jordan R Beach; George S Hussey; William P Schiemann; Thomas T Egelhoff; Philip H Howe; Donna E Hansel Journal: Am J Pathol Date: 2016-03-14 Impact factor: 4.307
Authors: Krystal Colon; Juliana Perez-Laspiur; Raymond Quiles; Yolanda Rodriguez; Valerie Wojna; Scott A Shaffer; John Leszyk; Richard L Skolasky; Loyda M Melendez Journal: Proteomics Clin Appl Date: 2015-11-18 Impact factor: 3.494